More Now Die in U.S. From Hepatitis C Than HIV
Many, Especially Baby Boomers, Don’t Even Know They’re Infected
Deciding Who Should Get the New Medications continued...
“In addition to the high cost, these drugs also have substantial side effect risks,” says researcher Jeremy Goldhaber-Fiebert, PhD, an assistant professor of medicine at the Stanford University School of Medicine. “Even for patients whom the drugs effectively cure, there is a real chance of feeling absolutely miserable during weeks of treatment.”
Goldhaber-Fiebert and his co-authors conclude that this triple therapy is cost-effective in all hepatitis C patients with advanced liver fibrosis, or scarring caused by inflammation, which can lead to cirrhosis.
He says a protease inhibitor might not be cost-effective as part of initial therapy in patients with mild liver fibrosis who have the genetic predisposition that responds well to the conventional treatment with pegylated interferon and ribavirin.
Ward and Goldhaber-Fiebert published their findings in the Annals of Internal Medicine.